Synthesize Possibilities, Degrade Despair
UPPthera Inc is a pharmaceutical venture company aiming for new drug development based on PROTAC technology
RESEARCH & DEVELOPMENT
Market driven R&D / Risk taking advance / Persistent Exploration
PROTAC (Proteolysis Targeting Chimaera) is next generation target protein degaradation platform employing ubiquitin-proteasome system in the body.
PROTAC consists of two linked protein binding molecules, one capable of engaging an E3 ubiquitin ligase and the other to a target protein meant for degradation.
UPPthera initially focuses on solving the certain unmet needs in the Metabolic disease and several cancers including hematologic malignancy, employing PROTAC technology.
(21988) 인천광역시연수구 송도미래로9 BRC 연구소 1동 204호